Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer

Background Efatutazone, a novel oral highly-selective peroxisome proliferator-activated receptor gamma (PPARγ) agonist, has demonstrated some inhibitory effects on disease stabilization in patients with metastatic colorectal cancer (mCRC) enrolled in previous phase I studies. Here, we evaluate the s...

Descripción completa

Detalles Bibliográficos
Autores principales: Komatsu, Yoshito, Yoshino, Takayuki, Yamazaki, Kentaro, Yuki, Satoshi, Machida, Nozomu, Sasaki, Takahide, Hyodo, Ichinosuke, Yachi, Yutaka, Onuma, Hiroshi, Ohtsu, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045340/
https://www.ncbi.nlm.nih.gov/pubmed/24337768
http://dx.doi.org/10.1007/s10637-013-0056-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045340/
https://www.ncbi.nlm.nih.gov/pubmed/24337768
http://dx.doi.org/10.1007/s10637-013-0056-3

Ejemplares similares